Eotaxin _ CCL11
- Known as:
- Eotaxin _ CCL11
- Catalog number:
- PA1140
- Product Quantity:
- 2 µg
- Category:
- -
- Supplier:
- ACR
- Gene target:
- Eotaxin _ CCL11
Related genes to: Eotaxin _ CCL11
- Gene:
- CCL11 NIH gene
- Name:
- C-C motif chemokine ligand 11
- Previous symbol:
- SCYA11
- Synonyms:
- eotaxin, MGC22554
- Chromosome:
- 17q12
- Locus Type:
- gene with protein product
- Date approved:
- 1996-04-24
- Date modifiied:
- 2016-10-05
Related products to: Eotaxin _ CCL11
Related articles to: Eotaxin _ CCL11
- (PV) is a severe autoimmune blistering disease characterized by pathogenic autoantibodies primarily targeting desmoglein-3. B-cell depletion by rituximab (anti-CD20) is an effective first-line treatment for PV; however, relapses are frequently observed. Evidence suggests that PV is associated with immune dysregulation beyond the B-cell compartment. So far, existing studies have largely focused on selected immune components or populations, or specific clinical states such as active disease, remission, or immediate post-rituximab, leaving it unclear how prior rituximab treatment shapes the overall circulating immune landscape during active PV, including relapse. In this study, we performed high-dimensional immune profiling to characterize circulating immune-cell composition and cytokine/chemokine signatures using a 40-colour spectral flow cytometry panel and a 46-plex Luminex assay, respectively. We compared active PV patients with healthy controls and performed a subgroup analysis of rituximab-naive versus rituximab-experienced relapsed PV patients. High-dimensional immune profiling showed that active PV is associated with a redistribution of circulating immune cells, with increased monocytes and decreased lymphocytes and plasmacytoid dendritic cells, together with reduced frequencies of double-negative (CD4CD8) T cells and T follicular helper cells compared with healthy controls. When comparing rituximab-naive with rituximab-experienced PV patients, in rituximab-experienced patients, the cellular composition changes were confined to the B-cell compartment, showing a shift toward a naive-dominant B-cell subset distribution. In parallel, PV was characterized by elevated serum concentrations of CD40L, CCL11/eotaxin, G-CSF, IL-1RA, IL-7, CCL20/MIP-3α, PD-L1/B7-H1/CD274, PDGF-AB/BB, and CCL5/RANTES, while no differences were identified between rituximab-naive patients and rituximab-experienced relapsed PV patients. Correlation analysis revealed that prednisone dosage may increase the frequency of mature B cells, and levels of CCL11/eotaxin, and IL-7, while decreasing the frequency of plasmacytoid dendritic cells and T follicular helper cells. Together, these findings reveal a systemic immune signature of active PV involving changes in circulating monocyte, T-cell, and soluble immune compartments, whereas prior rituximab exposure in relapsed patients is associated with sustained remodelling confined to B-cell subset composition, without long-term restructuring of non-B-cell immune lineages. - Source: PubMed
Publication date: 2026/08/03
Strandmoe Anne-LiseBonasia Carlo GInrueangsri NanthichaAbdulahad Wayel HStrating Inge MMennega Kevin PBijma TheoDiercks Gilles F HBremer JeroenLaman Jon DHorváth BarbaraHeeringa Peter - Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is frequently associated with gastrointestinal manifestations; however, intestinal immune responses following SARS-CoV-2 infection remain incompletely understood. This study aimed to characterize eosinophil-associated intestinal immune responses in SARS-CoV-2-infected K18-hACE2 transgenic mice. - Source: PubMed
Publication date: 2026/08/12
Tamaki ShunKawashima ReiUematsu TakayukiKawakami FumitakaImai MotokiKurosaki YoshifumiMatsumoto ToshihideMaehana ShotaroHara YusukeSugawara SetsukoIzawa HirokiIchikawa TakafumiKitasato HideroHanaki HideakiKubo Makoto - Major depressive disorder (MDD) is a prevalent mental illness with a significant disease burden. It is characterized by immune-inflammatory dysregulation. - Source: PubMed
Chen TangcongLuo YueyangNiu MengqiLi JingLi MengdieZhang YingqianMaes Michael - Plasma inflammatory protein biomarkers associated with clinical milestone heterogeneity in Parkinson's disease (PD) remain undefined. We measured 92 inflammation-related plasma proteins in 82 PD patients using the Olink Proximity Extension Assay. No proteins differed significantly between fallers and non-fallers. However, among fallers, plasma interleukin-24 showed the strongest correlation with observed time to first fall (unadjusted r = 0.752, q = 0.071), and this signal was also observed in an exploratory covariate-adjusted model (q = 0.030). Colony-stimulating factor 1 showed a comparable but non-significant correlation. In group comparisons for symptomatic orthostatic hypotension, CCL11 differed significantly between patients with and without symptomatic orthostatic hypotension (q = 0.0004). These exploratory findings highlight candidate inflammatory protein profiles related to milestone heterogeneity in PD, warranting validation in longitudinal cohorts. - Source: PubMed
Publication date: 2026/07/31
Iwaoka KazuhiroTaguchi KeitaOikawa SayuriToyoshiba HiroyoshiAndo TatsuyaMaeda Tetsuya - In order to investigate the therapeutic mechanism of Jianpiyiqi Granule in juvenile myasthenia gravis (JMG) and find the immune-associated cytokines or signaling pathways targeted by this intervention. - Source: PubMed
Geng YuanyuanLiu PengJin MinQi GuoyanLin XiaotingZhang Yousheng